SOURCE: Shinesrooms.com

Shinesrooms.com

August 08, 2012 08:15 ET

Equity Research on Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. - Strong Quarter for Diagnostic Substances

NEW YORK, NY--(Marketwire - Aug 8, 2012) - www.ShinesRooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Diagnostic Substances industry and are offering free analytical research on Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and IDEXX Laboratories Inc. (NASDAQ: IDXX). Register with us now to have free access to these research reports. Simply click on the link below.

http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index

Strong competition, costly drug trials and unfavorable currency exchanges are making it difficult for companies within the diagnostic substances industry to widen margins but not impossible. Get your free reports on Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. at http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.

ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Raptor Pharmaceuticals Corp. and IDEXX Laboratories Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing. 

www.ShinesRooms.com

IDEXX Laboratory Corp. provides a good example of the adverse effects of macroeconomic headwinds. The company saw revenues dented by unfavorable currency rates in the last quarter but still managed to see organic revenue growth of 7% which is encouraging moving forward. IDEXX Laboratories Inc. report is accessible for free by registering today at

http://www.ShinesRooms.com/IDEXXLaboratoriesInc080812.pdf

Maintaining a steady pipeline of drugs to market is perhaps as important as ever considering the current high levels of competition. This is especially so for treatments of rare diseases with small patient bases. The nephropathiccystinosis market illustrates this point. Currently, Mylan's Cystagon is the only available treatment but Raptor Pharmaceutical Corp.'s RP103 continues to make progress in its bid for approval. It could see approval as early as January of next year and significantly alter the current market. Raptor Pharmaceuticals Corp. report is accessible for free by registering today at

http://www.ShinesRooms.com/RaptorPharmaceuticalsCorp080812.pdf

The two Diagnostic Substances stocks research reports are available for free by signing up now on the link below.

www.ShinesRooms.com

About Shinesrooms.com

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.

Contact Information